# Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

> **NCT04790851** · PHASE4 · COMPLETED · sponsor: **China National Biotec Group Company Limited** · enrollment: 1133 (actual)

## Conditions studied

- Influenza, Human
- Pneumonia, Pneumococcal
- Covid19

## Interventions

- **BIOLOGICAL:** COVAX+IIV4; COVAX+PPV23
- **BIOLOGICAL:** COVAX only (1st and 2nd dose)
- **BIOLOGICAL:** IIV4 for the 1st dose and PPV23 for the 2nd dose

## Key facts

- **NCT ID:** NCT04790851
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2021-09-05
- **Final completion:** 2021-09-05
- **Target enrollment:** 1133 (ACTUAL)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790851, "Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04790851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*